Searching for keyword:"Endotoxemia"

60 results
Record publications over time
Ironsift results are limited for unregistered users. Register or log in to see all records.

US Clinical Trial NCT02675868 – NIH – Jan 25, 2016

The Effects of Different Vasopressors on the Innate Immune Response During Experimental Human Endotoxemia, a Pilot Proof-of-principle Study

Rationale: Septic shock is a major medical challenge associated with a high mortality rate and increasing incidence. It has become clear that the majority of septic patients do not succumb to an initial pro-inflammatory "hit", but at a later time-p...
Full record

US Clinical Trial NCT00184990 – NIH – Sep 12, 2005

Effect of Selective iNOS Inhibition During Human Endotoxemia

No preview available.
Full record

US Clinical Trial NCT00197899 – NIH – Sep 13, 2005

No preview available.
Full record

US Clinical Trial NCT01474629 – NIH – Nov 16, 2011

Impact of Supplementation With Probiotics on Exercise-induced Oxidative Stress and Endotoxemia in Trained Men

No preview available.
Full record

US Clinical Trial NCT02922673 – NIH – Sep 26, 2016

The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia

No preview available.
Full record

US Clinical Trial NCT02127749 – NIH – Apr 28, 2014

The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia

Rationale: Sepsis ranks among the top ten leading causes of death worldwide. Most nonsurvivors die in a state of immunosuppression. The gut microbiota exerts numerous beneficial functions in the host response against infections. Gut flora components...
Full record

US Clinical Trial NCT02825329 – NIH – Jul 4, 2016

Evaluating the Use of Polymyxin B Hemoperfusion in a Prospective Non-controlled Trial in Adults

This is an open-label, non-controlled trial of standard medical care plus the TORAYMYXIN PMX-20R (PMX cartridge), in subjects with endotoxemia and septic shock. Subjects in ICUs will be assessed for septic shock using known or suspected infection an...
Full record

US Clinical Trial NCT03413735 – NIH – Jan 22, 2018

Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults

Obesity is a major public health concern in the United States, with over two-thirds of the adult population classified as overweight or obese. Obesity is characterized by low-grade chronic inflammation that, in part, is mediated by metabolic endotox...
Full record

US Clinical Trial NCT01046669 – NIH – Jan 8, 2010

Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock

No preview available.
Full record

US Clinical Trial NCT03482284 – NIH – Mar 20, 2018

Exploratory Study on the Modulation of Endotoxemia and Metabolic Parameters: Role of Macronutrients

In the intervention study normal weight participants will receive defined amounts of monosaccharides for several days. Before and after intervention parameters of intestinal barrier function will be assessed.
Full record

US Clinical Trial NCT02107560 – NIH – Apr 3, 2014

A Comparison of Results With Bile and Blood Culture in Patients With Acute Cholangitis According to Severity

No preview available.
Full record
Register to view full records and disable ads.

US Clinical Trial NCT02346838 – NIH – Jan 7, 2015

The Effect of Prebiotics on Insulin Sensitivity, Metabolic Flexibility, and Cardiovascular Health in Prediabetic Adults.

Prebiotics have been defined as "selectively fermented ingredients that result in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring health benefit(s) upon host health". Commonly used prebiotics a...
Full record

US Clinical Trial NCT00284869 – NIH – Jan 31, 2006

Ethnic Differences in the Inflammatory Response in Systemic Inflammation

Recent data show that there are significant disparities among genders and races in the incidence of sepsis. While men are consistently more likely to have sepsis than women, the apparent racial disparities are even more striking, approaching a doubl...
Full record

US Clinical Trial NCT03860584 – NIH – Feb 28, 2019

Alleviation Of Metabolic Endotoxemia In Adults With Metabolic Syndrome With Milk Fat Globule Membrane

Background and hypothesis: Our preclinical evidence shows that phospholipid-rich milk fat globule membrane (MFGM) attenuates lipopolysaccharide-induced increases in gut permeability and pro-inflammatory cytokines. MFGM also attenuates inflammation...
Full record

US Clinical Trial NCT03158363 – NIH – May 16, 2017

A New Model of Acute Febrile Disease - Combining Endotoxemia, Immobilisation and Fasting in Healthy Young Males.

The investigators want to establish a new model of acute febrile disease by mimicking the conditions seen in hospitalized patients in regards to inflammation, immobilisation and fasting. In this new model of disease, healthy young adults will be giv...
Full record

US Clinical Trial NCT01100996 – NIH – Apr 7, 2010

The Effect of Enriched Enteral Nutrition on Inflammation and Sub-clinical Organ Dysfunction During Human Endotoxemia

No preview available.
Full record

US Clinical Trial NCT03901807 – NIH – Apr 2, 2019

A Prospective, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of PMX Cartridge in Addition to Standard Medical Care for Patients With Endotoxemic Septic Shock

This is a prospective, multicenter, randomized, open-label trial of standard medical care plus the PMX cartridge versus standard medical care alone, in subjects with endotoxemia and septic shock. Subjects in critical care areas will be assessed for...
Full record

US Clinical Trial NCT02074280 – NIH – Feb 15, 2014

Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial

Cirrhotic patients are predisposed to intestinal dysmotility, bacterial overgrowth, and increased intestinal permeability all leading to an increase in bacterial translocation and increased endotoxemia. Cirrhotics with bacterial translocation and en...
Full record

US Clinical Trial NCT01766414 – NIH – Jan 4, 2013

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - A Randomized Controlled Pilot Study

No preview available.
Full record

US Clinical Trial NCT00513110 – NIH – Aug 7, 2007

A Possible Therapeutic Role for Adenosine During Inflammation

No preview available.
Full record

US Clinical Trial NCT03240497 – NIH – Jul 19, 2017

The Influence of Breathing Techniques and Exposure to Cold on Inflammation During Human Endotoxemia, an Explorative Study'

Auto-immune diseases are characterized by an inappropriate inflammatory response against tissues in the body. These diseases, of which rheumatoid arthritis (RA) is the most well-known, represent a major health care burden. Pro-inflammatory cytokines...
Full record
Register to view full records and use our APIs.

US Clinical Trial NCT02875028 – NIH – Jun 27, 2016

Vorapaxar in the Human Endotoxemia Model A Randomized, Double‐Blind, Crossover Study

Vorapaxar is a novel platelet inhibitor inhibiting PAR-1. It is the first available substance of a new class of platelet inhibitors blocking the activation of platelets via thrombin or thrombin receptor activating peptides via PAR-1. As platelets co...
Full record

US Clinical Trial NCT01176942 – NIH – May 24, 2010

Probiotics and Endotoxemia in Humans

No preview available.
Full record

US Clinical Trial NCT00309374 – NIH – Mar 30, 2006

Anti-Inflammatory Effect of Statins in the Human Endotoxin Model

The beneficial effect of lipid lowering in cardiovascular disease is well established. Statin potently reduce elevated cholesterol levels but also exert pleiotropic other effects such as improvement of inflammation-induced vascular dysfunction, upre...
Full record

US Clinical Trial NCT01091571 – NIH – Mar 18, 2010

The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia.

No preview available.
Full record

US Clinical Trial NCT02521779 – NIH – Jul 28, 2015

Dietary Fat Affects Postprandial Serum Endotoxin Concentration in Healthy Adults

No preview available.
Full record

US Clinical Trial NCT03973996 – NIH – May 30, 2019

Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome

Tea is the most abundantly consumed prepared beverage in the world. Green tea, containing catechins, exerts antiinflammatory activities. However, a fundamental gap exists concerning its intestinal-level targets that can prevent metabolic syndrome (M...
Full record

US Clinical Trial NCT03624569 – NIH – Aug 2, 2018

Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome

Cardiovascular disease is a major public health concern in the United States, where it accounts for 1 in 4 deaths every year. Vascular endothelial dysfunction is an early event leading to cardiovascular disease and can be caused by postprandial hype...
Full record

US Clinical Trial NCT03319550 – NIH – Oct 13, 2017

Whey vs Casein to Combat Post-inflammatory Protein and Muscle Waste - Combining Endotoxemia, Immobilisation and Fasting in Healthy Young Males in a New Model of Acute Febrile Disease

Background: Acute illness is accompanied by infection/inflammation, anorexia and immobilization all contributing to muscle loss, making nutritional supplement optimization an obvious target for investigation and eventually clinical intervention. In...
Full record

US Clinical Trial NCT02629874 – NIH – Nov 16, 2015

Randomized Double Blind Placebo-controlled Clinical Safety, Tolerability and Pharmacokinetic/-Dynamic Study on the Effects of Escalating Single Intravenous Doses of EA-230 on the Innate Immune Response During Experimental Human Endotoxemia

Although the immune system is essential to survival, a variety of diseases originate from inappropriate activation of the immune response. Besides a range of auto-inflammatory disease like rheumatoid arthritis, inappropriate or undesirable activatio...
Full record

US Clinical Trial NCT01249378 – NIH – Jul 13, 2010

Metabolic Impact of the Digestion of Fat in Emulsified vs Non-emulsified Form in Lean or Obese Volunteers

No preview available.
Full record
Register to view full records and receive email notifications.

US Clinical Trial NCT01349699 – NIH – May 5, 2011

Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia

Systemic inflammation is accompanied by profound changes in iron distribution, mainly under the influence of hepcidin, leading to sequestration of iron in macrophages of the reticuloendothelial system, and ultimately anemia of inflammation. This red...
Full record

US Clinical Trial NCT03754504 – NIH – Nov 19, 2018

Evaluation of the Effect of Cranberry Whole Fruit Powder on Gut Microbiota Diversity, Intestinal Health and Metabolic Syndrome in Overweight Individuals: a Proof-of-concept Study

Over the past decade it has become clear that the gut microbiota is a key determinant of obesity and that its perturbations by nutritional insults play a significant role in the development of metabolic complications such as insulin resistance, type...
Full record

US Clinical Trial NCT03800277 – NIH – Dec 6, 2018

Effect of Prebiotic Supplementation on Metabolic Endotoxemia and Modulation of the Gut Microbiota: Double-blind, Controlled and Randomized Parallel Clinical Study of the Efficacy and Synergistical Effect of Cranberry Polyphenols and Inulin From Agaves

It is now recognized that overweight individuals have altered microbiota which could lead to intestinal barrier defects and chronic inflammation disorders. Polyphenols such as Proanthocyanidins may modulate the gut microbiota thereby providing benef...
Full record

US Clinical Trial NCT02612480 – NIH – Nov 3, 2015

The Effect of Ticagrelor on the Inflammatory Response to Human Endotoxemia

No preview available.
Full record

US Clinical Trial NCT02876601 – NIH – Jun 27, 2016

Defibrotide in the Human Endotoxemia Model -- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide

Defibrotide (DF) is a highly complex polydisperse mixture of single-stranded phosphodiester oligodeoxyribonucleotides derived from the controlled depolymerization of porcine intestinal mucosal DNA. The entire mode of action remains unknown. Its acti...
Full record

US Clinical Trial NCT00185003 – NIH – Sep 13, 2005

Blockade of Vascular Potassium Channels During Human Endotoxemia

No preview available.
Full record

US Clinical Trial NCT00246714 – NIH – Oct 28, 2005

Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans

See protocol
Full record

US Clinical Trial NCT01835457 – NIH – Mar 25, 2013

Concentration/Meditation as a Novel Means to Limit Inflammation: a Randomized Controlled Pilot Study

No preview available.
Full record

US Clinical Trial NCT00506454 – NIH – Jul 23, 2007

A Phase II, Double-Blind, Placebo-Controlled, Randomized Study of the Effects of a Lipid Emulsion (Lipidose) on Endotoxin Levels in Patients on Chronic Hemodialysis

Over 70% of dialysis patients suffer chronically from severe fatigue and tiredness. A possible inciting factor may be high levels of circulating endotoxin, which is well-established as a potent stimulator of inflammatory cytokine release. The sourc...
Full record

US Clinical Trial NCT01099566 – NIH – Apr 6, 2010

The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation

No preview available.
Full record
Register to view full records and advanced analytics.

US Clinical Trial NCT00332267 – NIH – May 31, 2006

Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia

The combination of acute infection and a low level of oxygen in the blood is a common phenomenon. Thus, acute hypoxia may complicate severe infections including severe sepsis. Conversely, healthy persons who ascend to moderately high altitudes, whic...
Full record

US Clinical Trial NCT00783068 – NIH – Oct 30, 2008

The Effect of the Alpha-7 Nicotinic AChR Agonist GTS-21 on Inflammation and End-organ Dysfunction During Human Endotoxemia

INTRODUCTION AND RATIONALE: The innate immune response is the first line of defense against invading pathogens(1). This tightly regulated system consists of a wide variety of chemokines, cytokines, cell associated receptors and other mediators orche...
Full record

US Clinical Trial NCT00046072 – NIH – Sep 19, 2002

A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis

No preview available.
Full record

US Clinical Trial NCT00413348 – NIH – Dec 18, 2006

Effect of Probiotics on Systemic Inflammation and Insulin Resistance in Type 2 Diabetics and Healthy Controls

Numerous studies have shown an association between insulin-resistance in type 2 diabetes and chronic low-grade inflammation. Some probiotics have an anti-inflammatory properties. Ingestion of probiotics might therefore, due to this property, increas...
Full record

US Clinical Trial NCT00413465 – NIH – Dec 18, 2006

Renal Plasma Flow During Experimental Human Endotoxemia

Many septic patients develop acute renal failure and the risk is higher in patients with diabetes. The pathogenetic mechanisms behind the development of acute renal failure in connection with sepsis is not completely understood. One among many possi...
Full record

US Clinical Trial NCT01374711 – NIH – May 19, 2011

The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia. A Parallel Randomized Double-blind Placebo-controlled Study

No preview available.
Full record

US Clinical Trial NCT02126072 – NIH – Apr 23, 2014

The Effects of Ethanol on Gut Wall Integrity as Measured by I-FABP and LBP

A common finding in trauma patients admitted to the ER with serious injuries is the presence of alcohol abuse. Alcohol is involved in up to 40% of deaths from motor vehicle crashes, 60% of deaths from intentional injuries, and 50% of hospital admiss...
Full record

US Clinical Trial NCT02186080 – NIH – Jul 4, 2014

Evaluation of the Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia Induced by High Fat Diet in Patients With Type 2 Diabetes

Study subjects will be allocated to either gemigliptin or placebo. After 4 weeks of treatment and 2 weeks of wash out period, all subjects will be switched to the opposite arm. The subjects will be tested oral fat tolerance test and adipose tissue...
Full record

US Clinical Trial NCT03864107 – NIH – Feb 14, 2019

Investigating the Possible Link Between Habitual Diet, Physical Activity, Sleeping Patterns, Obesity Status and Age With Gut Bacterial Composition, Gut Barrier Function, Metabolic Endotoxemia, Systemic Inflammation and Glycaemic Control.

No preview available.
Full record